Elder's Patalganga plant gets accreditation from Japan's health ministry.
03 Jan 2011
Elder Pharmaceuticals has received accreditation from Japan's ministry of health for its active pharmaceutical ingredients (API) plant at Patalganga in Maharashtra, Elder Pharma said in a statement to the Bombay Stock Exchange (BSE).
The accreditation will open up the fast growing Japanese markets for the company's products and strengthen Elder's position as a supplier of APIs and interrmediates, the statement added.
"Elder is positioning itself to be an API and advanced intermediate supplierv to the Japanese market. This accreditation for the API plant is a step towards strengthening Elder's position as a supplier of API and intermediates in the Japanese market," said Alok Saxena, director, Elder Pharma.
"The company has also developed two products going off patent in the Japanese market in 10214. One of the products is from CNS category and the second is from the GI segment," he added.
Elder, meanwhile, has broadly filed a PCT patent for one of the advanced intermediates for the Japanese market.
The pharmaceuticals market in Japan, valued at $69.4 billion in 2009, is the second-largest pharma market in the world.
Japan is increasing the share of its healthcare spends on generics and is targeting this to go up to 30 per cent in 2013, it added.
.jpg "RBI keeps repo rate unchanged as focus remains on inflation")
.jpg "Indian Oil, Panasonic team up for lithium-ion cell production in India")
